Droplet digital PCR for BCR/ABL(P210) detection of chronic myeloid leukemia: A high sensitive method of the minimal residual disease and disease progression
Droplet digital PCR for BCR/ABL(P210) detection of chronic myeloid leukemia: A high sensitive method of the minimal residual disease and disease progression
复制标题
微滴式数字PCR检测慢性粒细胞白血病BCR/ABL(P210)：微小残留病和疾病进展的高灵敏方法
DOI：
10.1111/ejh.13084
复制
发表时间：
2018-09-01
影响因子：
3.1
通讯作者：
Wang, Hong-Wei
中科院分区：
文献类型：
--
作者：
Wang, Wen-Jun;Zheng, Chao-Feng;Wang, Hong-Wei
ObjectiveThis study intended to establish a droplet digital PCR (dd-PCR) for monitoring minimal residual disease (MRD) in patients with BCR/ABL (P210)-positive chronic myeloid leukemia (CML), thereby achieving deep-level monitoring of tumor load and determining the efficacy for guided clinically individualized treatment.MethodsUsing dd-PCR and RT-qPCR, two cell suspensions were obtained from K562 cells and normal peripheral blood mononuclear cells by gradient dilution and were measured at the cellular level. At peripheral blood (PB) level, 61 cases with CML-chronic phase (CML-CP) were obtained after tyrosine kinase inhibitor (TKI) treatment and regular follow-ups. By RT-qPCR, BCR/ABL (P210) fusion gene was undetectable in PB after three successive analyses, which were performed once every 3months. At the same time, dd-PCR was performed simultaneously with the last equal amount of cDNA. Ten CML patients with MR4.5 were followed up by the two methods.ResultsAt the cellular level, consistency of results of dd-PCR and RT-qPCR reached R(2)0.99, with conversion equation of Y=33.148X(1.222) (Y: dd-PCR results; X: RT-qPCR results). In the dd-PCR test, 11 of the 61 patients with CML (18.03%) tested positive and showed statistically significant difference (P
